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ABSTRACT
Background. Epstein-Barr virus (EBV)-positive gastric can-
cers (GCs) have been recently identified as a molecular
subgroup showing excellent outcomes after surgery for
early-stage disease and responsiveness to immune
checkpoint inhibitors (ICIs) for metastatic stage. No data
are available on the prevalence, clinical characteristics,
and prognosis of this subgroup of GCs in the metastatic
setting.
Materials and Methods. In this cohort study, we assessed
the impact of EBV status in patients with metastatic GC
treated with chemotherapy at two Italian institutions.
Results. Among the 175 cases analyzed, only 7 (4%) were
EBV positive and all showed long-lasting and even complete
responses to first-line chemotherapy with fluorouracil and
platinum and a significantly better survival compared with
EBV-negative patients (3-year overall survival: 80% vs. 20.1%;
hazard ratio: 0.12).
Conclusion. If confirmed in larger data sets, our results may
give a strong rationale for investigating the addition of ICIs
to chemotherapy, in order to maximize the chance of achiev-
ing durable and complete responses in this uncommon sub-
type of GC. The Oncologist 2020;25:1–7
Implications for Practice: As of today, no data are available on the prevalence and clinical characteristics of patients
with Epstein-Barr virus (EBV)-positive metastatic gastric cancer (GC), a specific subtype of GC showing excellent out-
comes after radical surgery in early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs). This
cohort study showed that patients with EBV-positive GC who did not receive ICIs had exceptional, long-lasting, and
even complete responses to first-line chemotherapy with fluorouracil and platinum and a significantly better survival
compared with EBV-negative patients. If confirmed in larger series, these results may give a strong rationale for investi-
gating the combination of chemotherapy and ICIs to achieve durable and potentially complete response in this uncom-
mon subtype of GC.
INTRODUCTION
In The Cancer Genome Atlas (TCGA), four gastric cancer (GC)
subtypes were identified based on molecular profiling of pri-
mary tumors: Epstein-Barr virus (EBV) positive, which represent
less than 10% of cases and are characterized by extensive DNA
hypermethylation, PIK3CA mutations, CD274 and PDCD1LG2
amplifications (encoding for programmed death-ligand 1
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[PD-L1] and PD-L2, respectively), and activation of immune sig-
naling pathways; microsatellite instability (MSI) tumors, which
are detected in 7%–20% of GCs, with hypermutation and high
immune cell infiltration; and genomically stable (GS) and
chromosomal instability (CIN), reported in 20% and 50%,
respectively [1]. Because TCGA subtypes are assigned by
means of complex (epi)genomic and transcriptomic profiling
techniques, their clinical translation is challenging. However,
MSI and EBV can be easily assessed as individual and repro-
ducible biomarkers to identify the two corresponding molec-
ular subgroups in the clinical practice.
In resectable disease, the subgroup of patients with MSI-
high GC show a significantly better survival when compared
with the microsatellite stable (MSS) one, with lack of benefit
from neoadjuvant/adjuvant chemotherapy [2–5]. Similarly,
EBV-positive GC is characterized by the best outcomes after
radical surgery as compared with other molecular subtypes
[6], but the relatively lower prevalence has hampered the
investigation of its role as a predictive marker of the efficacy
of multimodality treatments. The excellent outcomes of the
MSI and EBV subgroups in radically resected early-stage dis-
ease are thought to be related to the host immune response,
which is driven by hypermutation and elevated neoantigen
load in the MSI subtype and by the persistency of the viral
infection in the EBV one.
In the metastatic setting, the prevalence of MSI is
extremely low (about 4% of cases) [7], as is also shown for
patients with metastatic colorectal cancer. The prognostic
impact of MSI in metastatic GC (mGC) in the pre-
immunotherapy era has been already explored, even if
the available data led to nonconclusive results. However,
the same studies are not available for the EBV subtype
so far. The aim of this report was to investigate the
prevalence, clinical-pathological-molecular characteristics,
chemotherapy response, and survival of patients with
EBV-positive mGC.
MATERIALS AND METHODS
Patients
We included patients with metastatic gastric or gastroesoph-
ageal junction (GEJ) cancers who were treated with chemo-
therapy at two Italian oncology departments: Fondazione
IRCCS Istituto Nazionale dei Tumori of Milan and University
Hospital of Modena. Patients treated with immune check-
point inhibitors (ICIs) were excluded. Tumor formalin-fixed
paraffin-embedded (FFPE) samples were collected from pri-
mary tumor or from metastases obtained before any sys-
temic therapy.
Medical records were reviewed to collect the following
characteristics: age, gender, primary tumor location (GEJ vs.
gastric body or antrum), Lauren histotype (intestinal vs. dif-
fuse vs. mixed), human epidermal growth factor receptor 2
(HER2) status, microsatellite instability (MSI-high vs. MSI-
low/microsatellite stable), primary tumor resection, time to
metastases (synchronous vs. metachronous), number of
metastatic sites, specific metastatic sites, treatments
received and survival outcomes.
Molecular Analyses
FFPE tumor tissue blocks obtained prior to the start of first-
line therapy were used for molecular analyses. EBV infec-
tion was evaluated by EBV-encoded RNA (EBER) in situ
hybridization (ISH). ISH was performed using a BenchMark
Ultra Platform (Ventana Medical Systems, Tucson, AZ),
according to the manufacturer’s instructions, using a cocktail
of oligonucleotide probes labeled with fluorescein. EBV posi-
tivity was defined as presence of blue nuclear staining in
tumor cells.
Microsatellite instability was assessed by means of multi-
plex polymerase chain reaction using five quasi-monomorphic
mononucleotide markers: BAT-25, BAT-26, NR-21, NR-24, and
MONO-27 (MSI Analysis System, version 1.2; Promega, Madi-
son, WI). Cases with instability at two or more of the five
markers were classified as MSI-high.
Statistical Analyses
The association between clinical, pathological, or molecular
characteristics and EBV status was analyzed using chi-square
test, Fisher’s exact test, or Mann-Whitney U test, as appro-
priate. Overall survival (OS) was defined as the time from
diagnosis of metastatic disease to death or last follow-up for
alive patients. Survival analyses were performed using the
Kaplan-Meier method and Cox proportional hazards regres-
sion models. Variables resulting significantly associated with
OS at the univariable analysis were fitted in a multivariable
model. A p value of less than .05 was considered statistically
significant. All statistical analyses were conducted using the
R software (version 3.5.0).
RESULTS
We included 290 patients with mGC treated from January
2011 to June 2019, of whom 35 were excluded because of
insufficient follow-up/clinical data and 80 because of insuffi-
cient tumor content in the centrally collected tumor blocks.
The remaining 175 patient were evaluable for this analy-
sis (Fig. 1).
Figure 1. CONSORT diagram of patients evaluated in our study.
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Among the overall population of 175 cases, EBV-positive
disease was found in 7 cases (4%). Table 1 shows patients’ and
disease baseline in the overall population and according to
EBV status. No clinicopathological characteristics differences
were observed between patients with EBV-positive and EBV-
negative metastatic gastric cancers. However, all EBV-positive
cases were MSS, intestinal-type, and HER2 negative. In the six
patients with EBV-positive mGC who received first-line therapy
with platinum and fluoropyrimidine combined chemotherapy,
response rate was 100%, with three partial and three com-
plete responses (Table 2).
At a median follow-up of 24.2 months, the median OS was
not reached in patients with EBV-positive mGC and 20.1
months (95% confidence interval [CI], 17.1–24.1) in patients
with EBV-negative mGC, with a 3-year survival rate of 80%
(95% CI, 51.6–100) and 26.5% (95% CI, 18.7–37.6), respectively
Table 1. Patients and disease baseline characteristics in the overall population and according to EBV status
Characteristics
Overall (n = 175),
n (%)
EBV positive (n = 7),
n (%)
EBV negative (n = 168),
n (%) p valuea
Age, years .066
Median 63 69 62
IQR 51–70 66–72 50–69
Gender .257
Female 66 (37.7) 1 (14.3) 65 (38.7)
Male 109 (62.3) 6 (85.7) 103 (61.3)
Site .439
Gastric body or antrum 121 (69.1) 6 (85.7) 115 (68.5)
Gastroesophageal junction 54 (30.9) 1 (14.3) 53 (31.5)
Histotype .203
Intestinal 109 (62.3) 7 (100) 102 (60.7)
Diffuse 53 (30.3) 0 53 (31.6)
Mixed 13 (7.4) 0 13 (7.7)
HER2 status .348
Positiveb 37 (21.1) 0 37 (22)
Negative 138 (78.9) 7 (100) 131 (78)
Time to metastases .999
Metachronous 32 (18.3) 1 (14.3) 31 (18.5)
Synchronous 143 (81.7) 6 (85.7) 137 (81.5)
Primary tumor resected .440
Yes 70 (40) 4 (57.1) 66 (39.3)
No 105 (60) 3 (42.9) 102 (60.7)
Number of metastatic sites .999
1 95 (54.3) 4 (57.1) 91 (54.2)
> 1 80 (45.7) 3 (42.9) 77 (45.8)
Liver metastases .675
No 127 (72.6) 6 (85.7) 121 (72.1)
Yes 48 (27.4) 1 (14.3) 47 (27.9)
Peritoneal metastases .712
No 91 (52) 3 (42.9) 88 (52.4)
Yes 84 (48) 4 (57.1) 80 (47.6)
Lymph node metastases .999
No 76 (43.4) 3 (42.9) 73 (43.5)
Yes 99 (56.6) 4 (57.1) 95 (56.5)
MSI status .999
MSI-low/MSS 160 (91.4) 7 (100) 153 (91.1)
MSI-high 15 (8.6) 0 15 (8.9)
aChi-square test, Fisher’s exact test, or Mann-Whitney U test, as appropriate.
bHER2-positive cases were defined as those with a score of 3+ at immunohistochemical staining (IHC) or IHC 2+ and amplified at the fluores-
cence in situ hybridization test.
Abbreviations: EBV, Epstein-Barr virus; HER2, human epidermal growth receptor 2; IQR, interquartile range; MSI, microsatellite instability; MSS,
microsatellite stable.
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(hazard ratio [HR], 0.12; 95% CI, 0.02–0.86; p = .035; Fig. 2). In
the multivariable model including the other characteristics
significantly associated with OS at the univariate analysis (i.e.,
primary tumor resection and number of metastatic sites), EBV
positivity confirmed an independent prognostic role (adjusted
HR: 0.12; 95% CI, 0.02–0.89; p = .038) as shown in Table 3,
whereas MSI status didn’t show any significant impact on sur-
vival (adjusted HR: 1.25; 95% CI, 0.57–2.70; p = .577).
Table 2. Patient characteristics, treatments received, and treatment-related outcomes in the subgroup of patients with
EBV-positive disease
Patient Gender Age
No. of
treatment
lines Treatment regimen
Best
responsea
No. of
treatment
cycles
Individual
patient
PFS, months
Individual
patient OS,
months
013 M 65 1 Docetaxel + oxaliplatin CR 6 51.8 52.8b
031 M 81 0 NAc NA NA NA 3.7b
032 M 59 1 FOLFOX CR 5 2.6d 5.6b
035 F 69 1 CAPOX CR 8 93.3 95.0b
068 M 67 1 FOLFOX PR 10 56.8 66.9b
156 M 69 2 FOLFOX (first line) PR 12 12.0 42.1
Paclitaxel + ramucirumab
(second line)
SD 6 6.4
172 M 74 2 FOLFOX (first line) PR 11 8.2 25.2
Paclitaxel + ramucirumab
(second line)
SD 8 3.3
aResponse were evaluated according to RECIST 1.1.
bPatient alive and progression-free at time of data cutoff (November 15, 2019).
cThis patient received only best supportive care.
dPatient still on treatment at time of data cutoff (November 15, 2019).
Abbreviations: CR, complete response; F, female; M, male; NA, not applicable; PR, partial response; SD, stable disease.
Figure 2. Kaplan-Maier survival curves according to molecular subgroups.
Abbreviations: CI, confidence interval; EBV, Epstein-Barr virus; HR, hazard ratio; OS, overall survival.
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DISCUSSION
In this study we used a simple, fast, and widespread assay
to assess EBV status in patients with mGC and we evaluated
the impact of EBV positivity on treatment outcomes and
prognosis with specific regard to the metastatic setting.
Our analysis shows that patients with EBV-positive mGC
have an extraordinarily good prognosis compared with
EBV-negative ones. This observation is in line with the
data obtained in patients with resectable early-stage dis-
ease [6, 8, 9] and is potentially related to the dramatic efficacy
Table 3. Cox proportional hazards regression models for OS
Characteristic
Univariate analysis Multivariable model
HR (95% CI) p value HR (95% CI) p value
Agea .404 —
51 Ref —
70 0.88 (0.65–1.19)
Gender .483 —
Female Ref —
Male 0.17 (0.75–1.81)
Site .754 —
Gastric body or antrum Ref —
Gastroesophageal junction 1.07 (0.70–1.65)
Histotype .200 —
Intestinal Ref —
Diffuse 1.45 (0.92–2.30)
Mixed
1.50 (0.68–3.32)
HER2 status .866 —
Positiveb Ref —
Negative 1.04 (0.64–1.69)
Time to metastases .084 —
Metachronous Ref —
Synchronous 1.71 (0.93–3.15)
Primary tumor resected .002 .004
Yes Ref Ref
No 2.05 (1.31–3.19) 1.97 (1.24–3.11)
Number of metastatic sites .033 .181
1 Ref Ref
> 1 1.56 (1.04–2.36) 1.34 (0.87–2.04)
Liver metastases .662 —
No Ref —
Yes 1.10 (0.71–1.72)
Peritoneal metastases .089 —
No Ref —
Yes 1.43 (0.95–2.16)
MSI status .610 —
MSI-low/MSS Ref —
MSI-high 1.22 (0.56–2.65)
EBV status .035 .038
Negative Ref Ref
Positive 0.12 (0.02–0.86) 0.12 (0.02–0.89)
aThe values represent the first and third quartile, respectively, of the variable distribution.
bHER2-positive cases were defined as those with a score of 3+ at immunohistochemical staining (IHC) or IHC 2+ and amplified at the fluores-
cence in situ hybridization test.
Abbreviations: —, not applicable; CI, confidence interval; EBV, Epstein-Barr virus; HER2, human epidermal growth factor receptor 2; HR, hazard
ratio; MSI, microsatellite instability; MSS, microsatellite stable.
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of cytotoxic chemotherapy and the chance of achieving
treatment-induced complete and/or durable response. We
should acknowledge that the relationship between the natural
history of EBV-positive mGC, the host immune response, and
the immunogenic cell death/antigen release induced by che-
motherapy cannot be easily established. Moreover, there has
been no systematic or preclinical investigation on the effect of
EBV infection on the chemosensitivity of EBV-associated
tumors. Finally, we also acknowledge that patients with
EBV-negative disease had relatively good survival in our series,
probably owing to a combination of several factors, such as
the continuous improvement of second- and further-line treat-
ments and the management at a tertiary cancer center.
In our series, the prevalence of MSI-high status was
relatively higher than the 4%–5% reported in clinical trials
[7, 10], which may be due to the usual limitations of cohort
studies and to potential differences between trial-eligible
and real-world patients with cancer. Regarding the prognos-
tic role of MSI, we did not show any significant OS difference
between patients with MSI-high versus MSS mGC. Even if all
available evidences are limited by the retrospective nature
and the extremely small sample size, a previous series
suggested a worse outcome of the patients’ subgroup with
MSI-high mGC after standard chemotherapy [11], but sur-
vival after relapse was not significantly different according
to MSI status in a recent meta-analysis of four trials [2].
However, several series in colorectal cancer showed that
MSI-high status turns from a positive prognostic biomarker
to a negative one when focusing on early versus metastatic
disease. Such aggressiveness of MSI-high metastatic disease
may be related to the elevated burden of immune suppres-
sion typical of advanced disease [12], and it is also due to
chemo- and anti-epidermal growth factor receptor resis-
tance [13–15].
Our data have clinical implications for the management of
patients with mGC and should be interpreted in light of the
growing evidence and strong biological rationale for the dra-
matic efficacy of ICIs in the EBV-positive molecular subgroup
[16, 17]. Although first-line pembrolizumab and combination
of chemotherapy plus pembrolizumab provided a significantly
higher benefit compared with chemotherapy alone in the
MSI-high subgroup [17], the specific benefit of adding chemo-
therapy to programmed cell death protein 1 (PD-1) blockade
in this patient population is yet to be determined. On the con-
trary, even if specific evidences from immunotherapy trials in
the EBV-positive subgroup are lacking, the use of immunother-
apy is biologically supported by the elevated T-cell infiltrate
and immune checkpoint expression in EBV-related cancers and
clinically confirmed by proof-of-concept studies [16]. Our
results highlight the importance of implementing EBV testing
in the future clinical practice and the strong rationale for the
design of molecularly stratified clinical trials. Even if the com-
parison of less toxic PD-1 blockade with chemotherapy in
patients with EBV-positive mGC is warranted, large-scale ran-
domized trials in this small subgroup are rather unfeasible. We
strongly encourage the design of proof-of-concept trials with
the combination of first-line chemotherapy and immunother-
apy, with the aim to maximize the chance of achieving durable
responses and potential disease cure in this uncommon sub-
type at risk of being neglected.
CONCLUSION
Even in need of further confirmation in larger data sets, the
extraordinarily good prognosis showed by patients with
EBV-positive mGC in our analysis may give a strong ratio-
nale for investigating the addition of ICIs to chemotherapy
in this uncommon subtype of GC.
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